Press coverage about Exelixis (NASDAQ:EXEL) has been trending positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Exelixis earned a coverage optimism score of 0.26 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.0204756534295 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news articles that may have effected Accern’s rankings:
Exelixis (EXEL) opened at 25.92 on Friday. The firm has a 50-day moving average of $26.15 and a 200-day moving average of $24.29. The company has a market capitalization of $7.62 billion, a PE ratio of 130.91 and a beta of 1.91. Exelixis has a 52 week low of $10.04 and a 52 week high of $32.50.
Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported $0.06 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.02. The business had revenue of $99.01 million during the quarter, compared to the consensus estimate of $85.27 million. Exelixis had a return on equity of 80.43% and a net margin of 18.20%. The firm’s revenue for the quarter was up 173.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.15) EPS. Equities analysts expect that Exelixis will post $0.28 earnings per share for the current fiscal year.
A number of research firms have weighed in on EXEL. Cann reissued a “hold” rating on shares of Exelixis in a research report on Monday, October 16th. Leerink Swann lowered shares of Exelixis from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $34.00 to $28.00 in a research report on Friday, September 22nd. Piper Jaffray Companies reaffirmed a “buy” rating and set a $29.00 price objective on shares of Exelixis in a research report on Thursday, August 3rd. Stifel Nicolaus reissued a “hold” rating and issued a $26.00 price target on shares of Exelixis in a research report on Thursday, August 3rd. Finally, Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Exelixis in a research report on Monday, October 16th. Six research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $31.38.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/10/27/exelixis-exel-receiving-positive-news-coverage-report-finds.html.
In other news, CFO Christopher J. Senner sold 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $26.79, for a total transaction of $2,679,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Stelios Papadopoulos sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, September 22nd. The stock was sold at an average price of $25.40, for a total value of $254,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 970,152 shares of company stock worth $25,923,457 over the last ninety days. Insiders own 5.10% of the company’s stock.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.